IRIS
ALTOMONTE, MARESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.644
EU - Europa 1.497
AS - Asia 804
SA - Sud America 138
Continente sconosciuto - Info sul continente non disponibili 68
AF - Africa 36
OC - Oceania 2
Totale 4.189
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.616
RU - Federazione Russa 397
SG - Singapore 317
IT - Italia 248
IE - Irlanda 216
GB - Regno Unito 215
CN - Cina 198
DE - Germania 160
VN - Vietnam 135
BR - Brasile 115
SE - Svezia 75
FR - Francia 72
UA - Ucraina 48
HK - Hong Kong 46
ZA - Sudafrica 25
BD - Bangladesh 22
ES - Italia 20
FI - Finlandia 20
IN - India 15
KR - Corea 12
CA - Canada 11
AR - Argentina 7
AZ - Azerbaigian 7
MX - Messico 7
CO - Colombia 6
JP - Giappone 6
TR - Turchia 6
IQ - Iraq 5
NL - Olanda 5
CH - Svizzera 4
EC - Ecuador 4
ID - Indonesia 4
KG - Kirghizistan 4
PK - Pakistan 4
SA - Arabia Saudita 4
JM - Giamaica 3
MY - Malesia 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
BG - Bulgaria 2
CR - Costa Rica 2
IM - Isola di Man 2
KZ - Kazakistan 2
MA - Marocco 2
MU - Mauritius 2
NG - Nigeria 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
IL - Israele 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 4.121
Salva come PNG Salva come JPEG
Città #
Dublin 215
Singapore 184
Fairfield 166
Southend 166
Ashburn 147
Dallas 126
Moscow 106
Santa Clara 83
Houston 82
San Jose 79
Woodbridge 78
Beijing 71
Cambridge 69
Wilmington 69
Milan 67
Seattle 57
Siena 47
Chandler 46
Hong Kong 44
Jacksonville 43
Dong Ket 38
Princeton 37
Ann Arbor 32
Ho Chi Minh City 32
Dearborn 31
Council Bluffs 28
New York 27
Lauterbourg 25
Hanoi 24
The Dalles 23
Johannesburg 21
Los Angeles 21
Rome 21
San Mateo 17
Shanghai 16
Málaga 15
Helsinki 14
Düsseldorf 13
Figino 13
Nanjing 11
San Diego 11
Stockholm 11
São Paulo 11
Portsmouth 10
Buffalo 9
Florence 9
London 9
Orem 9
Frankfurt am Main 8
Munich 8
Phoenix 8
Baku 7
Nuremberg 7
San Giovanni Valdarno 7
Atlanta 6
Hefei 6
Manchester 6
Nanchang 6
Toronto 6
Yongsan-gu 6
Boardman 5
Boston 5
Chicago 5
San Francisco 5
Venezia 5
Ankara 4
Bogotá 4
Brooklyn 4
Columbus 4
Hải Dương 4
Jinan 4
Las Vegas 4
Ninh Bình 4
Redondo Beach 4
Tianjin 4
Tokyo 4
Amsterdam 3
Bari 3
Belo Horizonte 3
Boydton 3
Campinas 3
Can Tho 3
Charlotte 3
Da Nang 3
Dhaka 3
Empoli 3
Goiânia 3
Guangzhou 3
Haiphong 3
Hangzhou 3
Karlsruhe 3
Kunming 3
Mexico City 3
Naples 3
Newark 3
Palermo 3
Rio de Janeiro 3
Schwielowsee 3
Seoul 3
St Petersburg 3
Totale 2.705
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 359
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 337
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 277
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 250
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 244
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 226
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 216
Biology and clinical applications of CD40 in cancer treatment 211
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 210
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 209
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 207
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 207
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 195
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 184
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 164
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 162
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 147
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort 137
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 126
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 121
Totale 4.189
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.885
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.885
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022173 0 0 20 3 4 11 7 11 13 26 25 53
2022/2023293 18 23 53 23 16 54 13 23 26 16 20 8
2023/2024292 15 4 23 11 4 78 113 6 5 1 15 17
2024/2025537 11 23 69 17 73 29 5 30 107 31 57 85
2025/20261.424 89 142 98 215 392 51 123 50 27 61 40 136
2026/2027184 89 54 41 0 0 0 0 0 0 0 0 0
Totale 4.189